Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Merck & Co appoints Frank Clyburn as president, human health

Clyburn joined the company in 2008, most recently serving as chief commercial officer for human health

- PMLiVE

Q&A: Avril Lee

PME interviews Zeno Group's Head of Healthcare, Europe and CIPR Diversity and Inclusion Network's Chair

There’s No Going Back: How COVID-19 will Change Pharma Forever

Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches...

Impetus Digital

Leading Successful Change Through Innovative Digital Technologies

Cassie Solomon, CEO of The New Group Consulting, dives into the future of innovation, digital technologies, and systems thinking in healthcare. Among many other things, we discuss how organizations can prepare...

Impetus Digital

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Lilly reports positive data from its phase 3 ulcerative colitis trial

IL-23 blocker mirikizumab helped patients achieve clinical remission in 12-week induction study

- PMLiVE

Healthcare PR agency Spink merges with emotive

Spink’s PR and public affairs expertise will become a part of emotive’s medical and brand offering

Accession Logo

Accession announces investment to support next phase of growth

March 2021: Accession Healthcare Consulting (Accession), a specialist pharma market access consultancy, today announces that it has received private investment from a group of highly experienced healthcare and technology investors...

Accession

- PMLiVE

EU considers blocking COVID-19 vaccine exports to the UK

EC president Ursula von der Leyen says she wants "to see reciprocity and proportionality in exports"

- PMLiVE

Merck & Co signs deal with Amathus for neurodegenerative diseases

Collaboration will focus on developing small molecules for undisclosed disease targets

- PMLiVE

UK COVID-19 vaccination drive hit with supply delays over the coming weeks

Weekly vaccine supplies face a 'significant reduction' from 29 March

- PMLiVE

A new era for UK-Japanese scientific research relations

Japan’s biopharmaceutical firms contributed $62.4bn, or 1.3% of GDP, to the country’s economic output in 2019

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links